| 1 |
35355383 | Hepatic drug metabolism in older people with body composition changes. | 2022 May |
1 |
| 2 |
32065000 | CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants. | 2020 Aug |
2 |
| 3 |
24990333 | The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. | 2014 |
1 |
| 4 |
25141173 | Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis. | 2014 |
6 |
| 5 |
20575631 | Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. | 2010 Jul |
1 |
| 6 |
19067473 | Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. | 2009 |
1 |
| 7 |
19652384 | Potential of lansoprazole as a novel probe for cytochrome P450 3A activity by measuring lansoprazole sulfone in human liver microsomes. | 2009 Aug |
3 |
| 8 |
17358097 | Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. | 2007 |
2 |
| 9 |
17361125 | Effects of uptake and efflux transporter inhibition on erythromycin breath test results. | 2007 Jun |
1 |
| 10 |
16755125 | Enantioselective disposition of lansoprazole and rabeprazole in human plasma. | 2006 Jun |
1 |
| 11 |
15752376 | Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. | 2005 Mar |
3 |
| 12 |
15856433 | Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. | 2005 Jun |
2 |
| 13 |
15010519 | Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. | 2004 May |
2 |
| 14 |
15370958 | Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. | 2004 May |
2 |
| 15 |
15496639 | Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. | 2004 Nov |
1 |
| 16 |
12975331 | Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. | 2003 Oct |
2 |
| 17 |
11829200 | Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. | 2001 Dec |
3 |
| 18 |
10859152 | Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. | 2000 Jul |
1 |
| 19 |
9021436 | Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. | 1997 Jan |
1 |
| 20 |
8627562 | Identification of the human P450 enzymes involved in lansoprazole metabolism. | 1996 May |
7 |
| 21 |
8930576 | Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. | 1996 Oct |
2 |
| 22 |
9165689 | Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. | 1996 May-Jun |
1 |
| 23 |
7656504 | Clinical pharmacokinetics of lansoprazole. | 1995 Jun |
1 |
| 24 |
8169844 | Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. | 1994 Apr |
5 |